1. An agent containing or consisting of (a) an antibody or antigen-binding fragment thereof with a specificity for human glandular kallikrein (hK2) and (b) a cytotoxic molecule for use in the treatment of prostate cancer. 2. The use of an agent containing or consisting of (a) an antibody or antigen binding fragment thereof specific for human glandular kallikrein (hK2) and (b) a cytotoxic molecule in the manufacture of a medicament for the treatment of prostate cancer. 3. A method for treating prostate cancer in a patient, which comprises the step of administering a therapeutically effective amount of an agent comprising or consisting of (a) an antibody or antigen binding fragment thereof specific for human glandular kallikrein (hK2) and (b) a cytotoxic molecule. 4. The tool, application or method according to any one of paragraphs. 1-3, where the antibody or its antigennegative fragment with specificity for hK2 competes for binding to hK2 with an antibody selected from the group consisting of 11B6 and 7G1.5. The tool, application or method according to any one of paragraphs. 1-3, where the antibody or its antigennegative fragment with specificity for hK2 contains one or more complementarity determining areas (CDRs) of an antibody selected from the group consisting of 11B6 and 7G1.6. The tool, application or method according to any one of paragraphs. 1-3, where the antibody or its antigen binding fragment with specificity for hK2 contains or consists of an antibody selected from the group consisting of 11B6 and 7G1 and their antigen binding fragments. 7. The tool, application or method according to any one of paragraphs. 1-3, where the antibody or its antigen binding fragment with hK2 specificity binds to the cytotoxic molecule1. Средство, содержащее или состоящее из (a) антитела или его антигенсвязывающего фрагмента со специфичностью к гландулярному калликреину человека (hK2) и (b) цитотоксической молекулы, для применения при лечении рака простаты.2. Применение сред
